-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下：葛兰素史克(GSK)公布了2026年第一季度业绩，销售额同比增长2%（固定汇率下为5%），超出预期。其中，特药业务表现尤为突出（同比增长10%或固定汇率下为14%），特别是肿瘤药物，Jemperli和Ojjaara的销量强劲增长。疫苗业务也实现了4%的固定汇率增长，这主要得益于Shingrix创纪录的销售额。核心每股收益(EPS)增长4%（固定汇率下为9%），达到0.465英镑，高于市场普遍预期的0.44英镑。这主要得益于有利的产品组合和成本控制，使得核心营业利润率提升了1.0个百分点（固定汇率下为1.8个百分点）。鉴于业绩超出预期且利润率有所提升，我们对第一季度业绩更新持积极态度，但我们也注意到汇率波动可能带来的不利影响。葛兰素史克重申了其2026年业绩指引，预计销售额增长3%-5%，核心营业利润（固定汇率）增长7%-9%。尽管这一预期较2025年增速有所放缓，但与赛诺菲和罗氏等多家同行公司的预期基本一致。我们预计，关键的专科药品将支撑营收增长，葛兰素史克的目标是到2031年，该业务板块的销售额占比超过50%（2026年第一季度：42%）。我们认为，近期的收购将为公司增长和药物研发管线注入强劲动力。
Related Articles
Mining & Metals
Fiera Capital Announcing Return of Maxime Menard As Global President and CEO
$FSZ.TO
Asia
HD Hyundai Energy Solutions Turns to Profit in Q1
HD Hyundai Energy Solutions (KRX:322000) posted first-quarter net income of 22.3 billion won, rebounding from a net loss of 1.08 billion won a year earlier, according to a Wednesday filing with the Korea Exchange.The South Korean solar energy equipment supplier's sales jumped 88% year over year to 159.9 billion won from 85.3 billion won.Shares of HD Hyundai Energy Solutions jumped more than 9% at market close.
$KRX:322000
Asia
Shandong Sunpaper's Attributable Profit Jumps 2% in Q1
Shandong Sunpaper's (SHE:002078) attributable profit rose 2.3% to 906.4 million yuan in the first quarter from 886.1 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the paper manufacturer increased to 0.3243 yuan from 0.3171 yuan in the prior-year period.Operating revenue grew 1.9% year over year to 10.1 billion yuan from 9.90 billion yuan.
$SHE:002078